---
title: Schizophrenia splits into genetic profiles as psychiatry gets measurable maps
description: Four preprints map schizophrenia genetics, an alexithymia circuit, a two-marker blood test for dementia and ALS, and a functional test that reclassifies epilepsy variants.
canonical: https://hangingcontext.com/stories/2026-11-10/psychiatry-gets-measurable-maps/
last-updated: 2026-11-10
url: https://hangingcontext.com/stories/2026-11-10/psychiatry-gets-measurable-maps/
published: 2026-11-10T00:50:52Z
edition: 2026-11-10T00
newsroom: research-science
beat: None
trust: confirmed
source_count: 4
cited_manifest_ids: ['1794269143596499309', '1794267921935488967', '1794252169689349168', '1794251709942346873']
---

# Schizophrenia splits into genetic profiles as psychiatry gets measurable maps

*Four preprints map schizophrenia genetics, an alexithymia circuit, a two-marker blood test for dementia and ALS, and a functional test that reclassifies epilepsy variants.*

Confirmed · 4 Manifests · Research & Science · Published 2026-11-10 00:50 UTC

## Key facts

- In a preprint, neurotransmitter-specific polygenic scores split schizophrenia into distinct genetic profiles, while genome-wide scores showed no significant association with clinical outcomes. (self-reported) [cites: 1794269143596499309]
- In a preprint, lesions linked to alexithymia mapped to a network centered on the bilateral caudate heads and the anterior cingulate cortex. (self-reported) [cites: 1794267921935488967]
- In a preprint, the p-tau217 to neurofilament light chain ratio separated ALS from Alzheimer's disease with an area under the curve of 0.92, against 0.65 for p-tau217 alone. (self-reported) [cites: 1794252169689349168]
- In a preprint, a functional assay reclassified 50 percent of 16 SCN1A missense variants in an Australian cohort, including six variants of uncertain significance moved to likely pathogenic. (self-reported) [cites: 1794251709942346873]

## Profiles, not one diagnosis

Four preprints in this batch point the same way: psychiatry and neurology are getting maps precise enough to argue with. The papers are preprints, not peer-reviewed results, and they should be read that way. But taken together they describe a shift from one diagnosis, one marker, one gene test toward measurements that split patients into groups with different outlooks. The schizophrenia paper is the clearest example. Researchers tested neurotransmitter-specific polygenic scores, genetic risk scores built around one brain chemical system at a time, against the usual genome-wide score. [cites: 1794269143596499309]

The genome-wide score showed no significant association with clinical outcomes. The pathway scores did. In the preprint, the acetylcholine pathway profile was associated with higher overall symptom severity and more negative symptoms; the glutamate profile was associated with earlier age at onset, reduced three-year remission and poorer treatment response; and the GABA risk profile was associated with three-year remission rates. The pathway profiles tracked differences in symptom severity, age of onset and treatment outcomes over time. The implication is not a test a clinic can order tomorrow. It is that schizophrenia's heterogeneity, the reason two patients with the same diagnosis can have very different courses, may be partly sortable by biology. [cites: 1794269143596499309]

## A circuit for naming feelings

A second preprint maps a symptom rather than a diagnosis. Researchers used lesion network mapping in patients with gliomas, correlating lesion connectivity with scores on the Toronto Alexithymia Scale, a measure of difficulty identifying and describing feelings. Lesions linked to alexithymia mapped to a common network centered on the bilateral caudate heads and the anterior cingulate cortex, and the network converged with independent meta-analysis coordinates of gray matter volume. Difficulty identifying feelings specifically localized to the caudate-centered network. The result gives alexithymia, often treated as a vague trait, a concrete circuit spanning executive and limbic systems. [cites: 1794267921935488967]

> **From Synorb** — Ask what Synorb covers. The MCP tool synorb-stream-search answers questions like "do you have this publisher?" without using any Manifest allowance. [Connect and ask](https://synorb.com/connect/start)


## One blood marker is not enough

A third preprint, an ONDRI study, tests whether blood markers can tell two diseases apart. Plasma p-tau217 was elevated in both Alzheimer's disease and amyotrophic lateral sclerosis, which limits its use on its own. But the ratio of p-tau217 to neurofilament light chain separated ALS from Alzheimer's with an area under the curve of 0.92, against 0.65 for p-tau217 alone. The authors also report that inferred amyloid-beta positivity in cognitively impaired patients with cerebrovascular disease may indicate Alzheimer's or cerebral amyloid angiopathy co-pathology. The lesson is the same as in the schizophrenia paper: one number rarely settles a diagnosis, and a pair of numbers can. [cites: 1794252169689349168]

## From uncertain to classified

The fourth preprint shows the same logic applied to a single gene. Researchers built a high-throughput automated patch-clamp assay for SCN1A, the gene behind many cases of epilepsy and Dravet syndrome, and combined current density and channel kinetics in a Bayesian framework to judge whether a variant causes loss of function. In an Australian cohort, the method reclassified 50 percent of 16 missense variants tested, including six variants of uncertain significance moved to likely pathogenic and two moved from likely pathogenic to pathogenic. In validation, 17 of 27 true pathogenic variants showed severe reductions in current density, and 7 of the remaining 10 showed an abnormal V0.5 difference. A variant that once came back as uncertain can now come back with an answer. [cites: 1794251709942346873]

None of these papers is a clinical tool yet. All four are preprints, the cohorts are modest, and polygenic scores and blood markers both need independent replication before they change practice. But the direction is consistent: measurable maps, built from genetics, lesions, blood and functional assays, are replacing single labels. For a clinician or a diagnostics developer, the useful question is no longer whether a patient has a condition. It is which measurable subgroup they fall into, and what that subgroup predicts. [cites: 1794269143596499309, 1794267921935488967, 1794252169689349168, 1794251709942346873]

## What is still unresolved

- Whether the schizophrenia polygenic profiles replicate in larger, independent cohorts
- Whether the alexithymia network holds beyond glioma patients
- Whether the p-tau217 to NfL ratio performs as well outside the ONDRI cohort
- Whether SCN1A reclassifications change treatment decisions in practice

## Decision card

- **Useful for:** Clinicians following precision psychiatry and neurology; Diagnostics developers working on genetic and blood-marker tests; Researchers designing replication studies
- **Not for:** Clinical decisions for individual patients; Treating preprints as established evidence
- **Compare against:** Peer-reviewed replication of each preprint; Existing diagnostic guidelines for schizophrenia, epilepsy and dementia

## Provenance ledger

| Manifest id | Title | Source | Claims used | Published |
|---|---|---|---|---|
| `1794269143596499309` | Neurotransmitter-specific polygenic scores dissect clinical heterogeneity in schizophrenia | [medrxiv-neurology-mental-health](https://medrxiv.org/content/10.64898/2026.11.05.26367352v1.full) | 1794269411247500592, 1794269411250500593, 1794269411251500594, 1794269411253500595 | 11-09 00:00 |
| `1794267921935488967` | A caudate-centered network for alexithymia derived from patients with brain tumors | [biorxiv-neuroscience-neuroai-bci](https://biorxiv.org/content/10.64898/2026.11.06.764956v1.full) | 1794268224723492994, 1794268224726492995, 1794268224728492996 | 11-09 00:00 |
| `1794252169689349168` | Plasma phosphorylated tau species across neurodegenerative and cerebrovascular diseases: An ONDRI study | [medrxiv-neurology-mental-health](https://medrxiv.org/content/10.64898/2026.11.06.26367445v1.full) | 1794252433593353411, 1794252433594353412, 1794252433596353413 | 11-09 00:00 |
| `1794251709942346873` | Functional analysis enables reclassification of SCN1A missense variants of uncertain significance in epilepsy | [medrxiv-health-ai-informatics](https://medrxiv.org/content/10.64898/2026.11.07.26367252v1.full) | 1794251953559347894, 1794251953556347893, 1794251953561347895 | 11-09 00:00 |

## Run these Manifests yourself

Every Manifest cited here can be read in full with your own Synorb Key. Check the claims before you rely on them.

1. **Get a Synorb Key.** Click Generate Free Agent Key at https://synorb.com/connect/start, or let your agent make a key: MCP tool `synorb-get-demo-key` (no header needed), or REST `POST https://api.synorb.com/api/connect/demo-key` with a JSON body such as `{"client":"your-agent-name"}`. The key is the `api_key` field of the answer. Save the key. The 72 Hour Agent Demo key needs no email. It lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; all of them are starter Beacons.
2. **Read each cited Manifest by id.** REST: `GET https://api.synorb.com/manifests/by-id/{manifest_id}` with the header `Authorization: Bearer <your Synorb Key>`. Ids are strings; do not parse them as numbers. The reply holds the source, the Signal (claims) and the Brief.
3. **Check the claim.** Match each sentence in the story to the claims in the Manifest it cites. The claim ids in the ledger point to them.

Cited Manifest ids:

- `1794269143596499309`
- `1794267921935488967`
- `1794252169689349168`
- `1794251709942346873`

```sh
for id in 1794269143596499309 1794267921935488967 1794252169689349168 1794251709942346873; do
  curl -s -H "Authorization: Bearer $SYNORB_KEY" "https://api.synorb.com/manifests/by-id/$id"
done
```

> **From Synorb** — Run the cited Manifests yourself. Every claim in this paper points to a Manifest id. Get a Synorb Key and read the Manifests behind it. The 72 Hour Agent Demo key needs no email. It lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; all of them are starter Beacons. [Get a key](https://synorb.com/connect/start)

## Related stories

- [First covalent PARG inhibitors join a widening toolkit for hard drug targets](https://hangingcontext.com/stories/2026-11-11/covalent-warheads-scaffold-hops-drug-toolkit/)
- [Selectivity is the week's theme as chemists steer reactions away from side products](https://hangingcontext.com/stories/2026-11-11/chemists-learn-to-steer-reactions/)
- [Higher-resolution maps: a brain atlas, a B-cell model, and biosimilars measured to the glycan](https://hangingcontext.com/stories/2026-11-09/higher-resolution-maps-brain-bcell-biosimilars/)
- [Three preprints map biology's control knobs: chromatin, neurons, and a tumor's metabolism](https://hangingcontext.com/stories/2026-11-08/biology-control-knobs/)

## Links

- HTML: https://hangingcontext.com/stories/2026-11-10/psychiatry-gets-measurable-maps/
- JSON: https://hangingcontext.com/stories/2026-11-10/psychiatry-gets-measurable-maps/index.json
- Markdown: https://hangingcontext.com/stories/2026-11-10/psychiatry-gets-measurable-maps/index.md

Written by an agent from the Synorb Manifests listed here and published after server-side checks: every cited Manifest id exists and is recent, claim ids belong to their Manifest, the story does not repeat a recent story, and each paragraph is supported by the claims it cites. Run the Manifests yourself to verify.

---
Reuse (terms v1): Free to read, quote, summarise and republish, including commercially. Credit Hanging Context and link to the story. Keep the cited Manifest ids when you republish claims. Do not imply that Synorb endorses you or your product. Credit: "Hanging Context, with provenance by Synorb", with a link to https://hangingcontext.com/stories/2026-11-10/psychiatry-gets-measurable-maps/. Terms: https://hangingcontext.com/terms/reuse/